Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Martins, V L ^a   Caley, M P ^a   Moore, K ^a   Szentpetery, Z ^a   Marsh, S T ^a   Murrell, D F ^b   Kim, M H ^b   Avari, M ^a   McGrath, J A ^c   Cerio, R ^a   Kivisaari, A ^d   Kahari V M ^d   Hodivala Dilke, K ^a   Brennan, C H ^e   Chen, M ^a   Marshall, J F ^a   O'Toole, E A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; MESSENGER RNA; PROTEOME; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VERY LATE ACTIVATION ANTIGEN 2; ANGIOGENESIS INHIBITOR; COL7A1 PROTEIN, HUMAN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; ENDOTHELIAL TUBE FORMING ASSAY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOME ARRAY; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TUMOR XENOGRAFT; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DRUG EFFECTS; DRUG SCREENING; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENETICS; METABOLISM; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA2BETA1; MICE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956574782     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv293     Document Type: Article

References (47)

1. Wang X, Ghasri P, Amir M, et al. Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure. Mol Ther. 2013;21(7):1335-1344.
2. Nystrom A, Velati D, Mittapalli VR, et al. Collagen VII plays a dual role in wound healing. J Clin Invest. 2013;123(8):3498-3509.
3. McGrath JA, Ishida-Yamamoto A, O'Grady A, et al. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression. J Invest Dermatol. 1993;100(4):366-372.
4. Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol. 2009;60(2):203-211.
5. Ortiz-Urda S, Garcia J, Green CL, et al. Type VII collagen is required for Rasdriven human epidermal tumorigenesis. Science. 2005;307(5716):1773-1776.
6. Pourreyron C, Cox G, Mao X, et al. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol. 2007;127(10):2438-2444.
7. Martins VL, Vyas JJ, Chen M, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122(Pt 11):1788-1799.
8. Kuttner V, Mack C, Rigbolt KT, et al. Global remodelling of cellular microenvironment due to loss of collagen VII. Mol Syst Biol. 2013;9:657.
9. Ng YZ, Pourreyron C, Salas-Alanis JC, et al. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res. 2012;72(14):3522-3534.
10. Vindevoghel L, Lechleider RJ, Kon A, et al. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc Natl Acad Sci USA. 1998;95(25):14769-14774.
11. Ryynanen J, Sollberg S, Olsen DR, et al. Transforming growth factor-beta up-regulates type VII collagen gene expression in normal and transformed epidermal keratinocytes in culture. Biochem Biophys Res Commun. 1991;180(2):673-680.
12. Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008;118(5):1669-1679.
13. Han G, Lu SL, Li AG, et al. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 2005;115(7):1714-1723.
14. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791.
15. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319-328.
16. Zambruno G, Marchisio PC, Marconi A, et al. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol. 1995;129(3):853-865.
17. Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115(2):339-347.
18. Huang X, Wu J, Spong S, et al. The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci. 1998;111(Pt 15):2189-2195.
19. Thomas GJ, Lewis MP, Whawell SA, et al. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol. 2001;117(1):67-73.
20. Chen M, Marinkovich MP, Veis A, et al. Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin. J Biol Chem. 1997;272(23):14516-14522.
21. Chen M, Costa FK, Lindvay CR, et al. The recombinant expression of fulllength type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa. J Biol Chem. 2002;277(3):2118-2124.
22. Nystrom ML, Thomas GJ, Stone M, et al. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol. 2005;205(4):468-475.
23. Kivisaari AK, Kallajoki M, Ala-aho R, et al. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol. 2010;163(4):726-735.
24. Giampieri S, Pinner S, Sahai E. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res. 2010;70(9):3435-3439.
25. Arbiser JL, Fine JD, Murrell D, et al. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med. 1998;4(3):191-195.
26. Murakami M, Nguyen LT, Hatanaka K, et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121(7):2668-2678.
27. Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med. 2004;10(7):693-695.
28. Dumartin L, Whiteman HJ, Weeks ME, et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res. 2011;71(22):7091-7102.
29. Barry S, Chelala C, Lines K, et al. S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clin Exp Metastasis. 2013;30(3):251-264.
30. Chen M, O'Toole EA, Li YY, et al. Alpha 2 beta 1 integrin mediates dermal fibroblast attachment to type VII collagen via a 158-amino-acid segment of the NC1 domain. Exp Cell Res. 1999;249(2):231-239.
31. Qu H, Tu Y, Shi X, et al. Kindlin-2 regulates podocyte adhesion and fibronectin matrix deposition through interactions with phosphoinositides and integrins. J Cell Sci. 2011;124(Pt 6):879-891.
32. Busk M, Pytela R, Sheppard D. Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem. 1992;267(9):5790-5796.
33. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factorbeta type I receptor kinase in vivo. Clin Cancer Res. 2006;12(14 Pt 1):4315-4330.
34. Margheri F, Schiavone N, Papucci L, et al. GDF5 regulates TGFss-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFss peptides. PLoS One. 2012;7(11):e50342.
35. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857-869.
36. Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33(13):1649-1657.
37. Mironchik Y, Winnard PT Jr, Vesuna F, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005;65(23):10801-10809.
38. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000-2008.
39. Banerjee A, Wu ZS, Qian PX, et al. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS One. 2012;7(11):e50098.
40. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008;65(5):700-712.
41. Ma L, Gauville C, Berthois Y, et al. Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. Oncogene. 1999;18(47):6513-6520.
42. Odorisio T, Di Salvio M, Orecchia A, et al. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-beta signalling in modifying disease severity. Hum Mol Genet. 2014;23(15):3907-3922.
43. Knaup J, Gruber C, Krammer B, et al. TGFbeta-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa. Anal Cell Pathol (Amst). 2011;34(6):339-353.
44. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979;115(6):703-705.
45. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-1113.
46. Chan TA, Glockner S, Yi JM, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008;5(5):e114.
47. Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008;128(9):2179-2189.